- Home
- XBIO vs NLSP Comparison
XBIO vs NLSP Comparison
Compare XBIO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- NLSP
- Stock Information
- Founded
- XBIO N/A
- NLSP 2015
- Country
- XBIO United States
- NLSP Switzerland
- Employees
- XBIO N/A
- NLSP N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- NLSP Health Care
- Exchange
- XBIO Nasdaq
- NLSP Nasdaq
- Market Cap
- XBIO 5.8M
- NLSP 5.9M
- IPO Year
- XBIO N/A
- NLSP 2021
- Fundamental
- Price
- XBIO $2.79
- NLSP $1.50
- Analyst Decision
- XBIO Hold
- NLSP
- Analyst Count
- XBIO 1
- NLSP 0
- Target Price
- XBIO N/A
- NLSP N/A
- AVG Volume (30 Days)
- XBIO 10.2K
- NLSP 102.6K
- Earning Date
- XBIO 05-08-2025
- NLSP 05-14-2025
- Dividend Yield
- XBIO N/A
- NLSP N/A
- EPS Growth
- XBIO N/A
- NLSP N/A
- EPS
- XBIO N/A
- NLSP N/A
- Revenue
- XBIO $2,500,284.00
- NLSP N/A
- Revenue This Year
- XBIO $14.23
- NLSP N/A
- Revenue Next Year
- XBIO N/A
- NLSP N/A
- P/E Ratio
- XBIO N/A
- NLSP N/A
- Revenue Growth
- XBIO N/A
- NLSP N/A
- 52 Week Low
- XBIO $2.20
- NLSP $1.30
- 52 Week High
- XBIO $5.20
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- XBIO 51.08
- NLSP 49.86
- Support Level
- XBIO $2.32
- NLSP $1.43
- Resistance Level
- XBIO $2.61
- NLSP $1.53
- Average True Range (ATR)
- XBIO 0.16
- NLSP 0.09
- MACD
- XBIO 0.08
- NLSP 0.02
- Stochastic Oscillator
- XBIO 89.76
- NLSP 64.91
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.